ADMINISTRATIVE SUPPLEMENT REQUESTS FOR STUDIES OF CANCER IN HIV/AIDS RELEASE DATE: April 2, 2003 NOTICE: NOT-CA-03-017 National Cancer Institute (NCI) (http://www.nci.nih.gov) In support of the National Cancer Institute objectives of Discovery, Development and Delivery, the Division of Cancer Treatment and Diagnosis (DCTD), has set apart funds in Fiscal Year 2003 specifically designated for studies of cancer in HIV+ populations and acquired immunodeficiency. It is DCTD's intention to foster clinical and basic investigators to interact in a coordinated, complementary, or synergistic manner to conduct translational research in AIDS malignancies. Investigators are encouraged to submit proposals for novel studies including but not limited to those that translate basic research findings into clinical application. Approved projects will be supported by administrative supplementation. The DCTD, NCI will provide NCI funded investigators conducting studies relevant to increasing our knowledge of the basic biology, pathogenic mechanisms, epidemiology, immunology, diagnosis, treatment, and prevention of cancer in the context of HIV/AIDS or other acquired immunodeficiency with supplemental funding for one year to conduct studies broadly related to a specific aim of the parent grant. To stimulate studies whose results provide new insights and increase our understanding of the pathobiology of cancer in the context of acquired immunodeficiency and HIV/AIDS and to facilitate progress in developing treatment and prevention modalities for these cancers. High risk, high impact studies not usually funded as traditional grants or exploratory projects in emerging areas of importance for malignancies in AIDS and other acquired immunodeficiencies are encouraged. Studies may be based on recent observations or take advantage of new technologies. Development of new methods or new technology is also encouraged. Studies may include but are not limited to studies of the viral and cellular processes involved in development and maintenance of cancer, etiology, epidemiology and natural history, laboratory correlative studies, therapeutic target identification, drug development, animal models, pre-clinical and clinical studies, and registry development. Interdisciplinary studies, translational studies, and relationship building between basic and clinical investigators are encouraged. The PI must have an active NCI funded grant with at least one full year remaining at the time of anticipated funding (September 30, 2003). Funding is limited to one year with a total cost limit of $100,000. PI salary support is not allowed. INQUIRIES For additional information on this AIDS Malignancy Program Initiative see http://www3.cancer.gov/dctd/initiatives.html or contact: Jodi B. Black, PhD Program Director, AIDS Malignancy Program Division of Cancer Treatment and Diagnosis (301) 402-6293 blackj@mail.nih.gov
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, RealPlayer, Video or Flash files, see Help Downloading Files. |